Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Plunged Today

By Joe Tenebruso - Feb 1, 2021 at 6:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst sounded a note of caution to investors.

What happened

Shares of Moderna (MRNA 4.97%) declined by 9% on Monday after Bank of America downgraded its stock. 

So what

Analyst Geoff Meacham cut his rating on Moderna from neutral to underperform and reiterated his price forecast of $150 per share. Meacham's estimate is roughly 13% below Moderna's closing price on Friday and 5% below its current price of $157.48.

A person is pointing to a digital stock chart that rises sharply and then falls.

Moderna's stock fell hard on Monday. Image source: Getty Images.

Meacham said investors are valuing Moderna's stock based on a "best-case" scenario of more than $85 billion in total coronavirus-related revenue, despite the potential for rising competition from rival COVID-19 vaccine makers like Johnson & Johnson and Novavax. Thus, he argues Moderna's share price is too high, as it does not properly reflect these risks.

Now what

Still, it should be noted that not all analysts are as bearish on Moderna's stock. Oppenheimer analyst Hartaj Singh actually boosted his stock price forecast from $178 to $206 and reiterated his outperform rating on Moderna on Monday. Singh said Moderna's ability to produce as many as 1 billion doses of its COVID-19 vaccine in 2021 gives it an edge over many of its competitors. 

Differing opinions among Wall Street analysts are common, particularly among coronavirus-related stocks. Moderna's stock price, in turn, is likely to remain volatile in the days and weeks ahead.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.95 (4.97%) $7.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.